Related Posts:
February 16, 2016
Swedish biotech company Dilaforette AB will partner with Arabian Gulf University (AGU) in Bahrain to conduct a Phase 2 clinical trial of sevuparin, a medication for patients with sickle cell disease (SCD) experiencing acute vaso-occlusive crisis. “Our collaboration with Dilaforette is a landmark moment for both parties,” AGU President Khalid bin Abdul Rahman Al-Ohaly said.
Read more →
Sign-up for the Weekly Newsletter from Gulf News Journal.